Ventracor sees bright future despite losses
This article was originally published in Clinica
Executive Summary
High expenditure on regulatory activities laid a significant dent in Ventracor's coffers, as the Australian developer of the VentrAssist left ventricle assist device recorded net loss of $36.5m for the year 2006/07. As it strives to expand its coverage in key international markets, the company said it spent heavily on guiding its lead technology through regulatory approvals in the US, Europe and Australia, but hopes to become profitable in the near future.
You may also be interested in...
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.